REMS Combined With TAI for Unresectable HC

Inclusion Criteria: * Clinically or histopathologically diagnosis of cholangiocarcinoma * With symptoms such as jaundice related to biliary obstruction * Biliary obstruction of Bismuth-Correlate Classification Type III or IV * Unresectable disease confirmed by multidisciplinary team * Maximum diameter of lesion ≤3 cm * Liver function of Child-Pugh A or B * 18 years older * With an expected survival time ≥ 3 months * With an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Meet the following laboratory test parameters: hematologic function (absolute neutrophil count ≥ 1.0×10⁹/L; platelet count ≥ 50×10⁹/L; hemoglobin ≥ 90 g/L; INR \< 1.7 or prolonged prothrombin time not more than 4 seconds); liver function (ALT/AST not more than 5 times the upper limit of normal; albumin ≥ 28 g/L); renal function (serum creatinine not more than 1.5 times the upper limit of normal) Exclusion Criteria: * Presence of distant metastases * With another malignancy type other than cholangiocarcinoma * Previous history of biliary stent placement * Moderate to severe ascites (ascites up to Child-Pugh score of 3) * Biliary perforation * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to enrollment * Unstable angina, myocardial infarction, coronary artery bypass graft, congestive heart failure, cerebrovascular accident (including transient ischemic attack, pulmonary embolism) within 3 months before enrollment * Persistent arrhythmia (CTCAE criteria grade 2 and above), atrial fibrillation of any degree, prolonged Qtc interval (more than 450 ms in men and more than 470 ms in women) * Refractory hypertension (blood pressure above 150/100 mmHg even after optimal drug therapy * Concomitant receipt of other anti-tumor drugs * Concomitant human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome * Pregnant or lactating women * Concomitant acute or chronic mental disorders (including mental disorders affecting subject enrollment, therapeutic intervention, and follow-up)